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these regions, and on an effort to better understand the 
challenges that Indian RTTs face. Not surprisingly, 
emphasized some of the same issues, namely, the need to 
treat high patient volumes and the need for improved 
implementation and training, particularly when it comes to 
software.  “Clinical users in their areas deal with very high 
numbers of patients each day. They also deal with limited 
skilled resources to use, fast, and as safe as they can be 
made,”  
Our objective is to come up with a set of guidelines for the 
career pathways, job roles at different level and the 
curricula for each level of the concerned profession. India’s 
greatest challenge will be to accomplish this but: The RTT 
management structure is majorly managed by senior policy 
makers from the medical fraternity, and provides very 
little scope for Technical professionals to participate in 
policy decision making and to bring about any reforms. 
Aims to provide world of RTTs with a global standard in the 
holistic care and treatment of patients as they undergo the 
radiotherapy process with optimum radiotherapy planning & 
 treatment techniques to patients now and in the future. The 
accuracy with which each step is carried out can have an 
impact on both tumour control and normal tissue 
complications.  
These factors mandate a high degree of accuracy in 
treatment delivery which depends on RTTs how he 
implemented and uses the Technology  
However, the change in technology and the required 
technical skills in RT over the past 10 years have been 
extreme and have forced major reviews of the technical 
aspect of RTT. We believe that the outcome of this meeting 
will be very useful for strengthening the education and 
therefore the role of RTTs in India and across the Globe to 
develop & promote the profile of the RTT within the 
multidisciplinary team in different regions under different 
challenges and, bring the resolution to the 1. Evaluation of 
technology: Relevant endpoints from the perspective of the 
RTT, Are we geared to implement technology in India and 
Skills to implement technology Training programs in India. By 
2020 RTTs of India will be more numerous, better educated, 
healthier and more prosperous than at any time in our long 
history. 
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Postoperative adjuvant chemotherapy is firmly established 
for patients in radically resected colon cancer with stage III 
and ‘high-risk’ stage II disease. In contrast, the debate 
continues to evolve on the benefit of postoperative adjuvant 
chemotherapy for rectal cancer patients after preoperative 
(chemo)radiation and TME surgery. Neither the indivividual 
phase III trials themselves nor the meta-analyses have 
provided a secure definitive answer for the benefit of 
postoperative adjuvant chemotherapy after SCPRT or CRT. 
Hence, several different strategies have been employed to 
escalate the intensity of chemotherapy in the neoadjuvant or 
preoperative setting.  
1) Integrating additional chemotherapy/targetted agents into 
preoperative chemoradiation (CRT) schedules 
2) Integrating induction chemo (IC) prior to CRT or short 
course preoperative radiotherapy SCPRT.    
3) Integrating induction chemo (IC) alone as an alternative to 
CRT or SCPRT. 
 
4) Integrating consolidation chemo (CC) after CRT or 
SCPRT.                                                                      
5) Alternating/interpolating chemotherapy and split course 
radiotherapy (ACAR) 
6) Combinations of the above  
These strategies are explored individually and the relevant 
trials examined.  The most frequent stragey has been 
concurrent chemoradiation and Phase III studies evaluated 
low-dose oxaliplatin (50-60mg/m2) as a radiosensitizer in 
patients with resectable cancers. This strategy increased 
acute toxicity, but showd no evidence for any consistent 
improvement in short-term endpoints such as pCR or long-
term oncological outcomes. So alternative manoevres as 
above using oxaliplatin at full systemic doses are being 
explored to see if this tactic can improve DFS or OS in 
borderline/unresectable patients where the CRM is 
compromised or cancers with high risk features for 
metastatic disease such as EMVI.  
Induction chemotherapy (IC) is a potentially useful 
therapeutic approach for locally advanced operable, 
primarily unresectable or borderline resectable rectal 
cancer. IC may be a more effective  option for patients with 
rectal cancer who would require adjuvant chemotherapy 
according to clinical and histological parameters, and MRI-
based imaging. The use of neoadjuvant systemic therapy in 
operable rectal cancer has potential advantages that include 
higher rates of sphincter-sparing surgery and the possibility 
of measuring early in-vivo response to systemic treatment. 
However, neoadjuvant treatment require a close 
collaboration between surgeons, medical oncologists, 
radiation oncologists, radiologists and pathologists.  
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Preoperative radio(chemo)therapy is a preferable treatment 
because it is more effective and less toxic than postoperative 
radiochemotherapy. There are two schedules of preoperative 
radiotherapy: 5 x 5 Gy delivered over 5 days with immediate 
surgery used for resectable cancers and conventionally 
fractionated radiochemotherapy delivered over 5 weeks with 
surgery delayed for 6 weeks used for both resectable cancers 
and for cancers with threatened mesorectal fascia. There 
were several prospective and retrospective trials, systematic 
reviews and one meta-analysis that explored the issue of 
increasing the rest period between radiation and surgery. 
Stockholm III randomized trial that compared immediate with 
delayed surgery after 5 x 5 Gy showed a benefit in terms of 
lower rate of severe acute post-radiation toxicity in the 
immediate-surgery group. However, this benefit was 
counterbalanced by the increase in minor postoperative 
complications in the group with immediate surgery compared 
with that with delayed surgery. Long-term results are 
awaited. Regarding elderly patients who were unfit for 
chemotherapy, 5 x 5 Gy with delayed surgery produced 
favourable outcomes for cancers with threatened mesorectal 
fascia or for small cancers after full-thickness local excision. 
5 x 5 Gy and consolidation chemotherapy during a long 
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interval to surgery is a promising treatment because the 
pathological complete response (pCR) rate of over 20% was 
recorded. The body of evidence from studies that used 
conventionally fractionated radiochemotherapy showed that, 
with a longer interval to surgery, the pCR rate and 
downstaging increased, whereas the R0 resection rate, the 
sphincter preservation rate and the long-term oncological 
outcomes remained much the same. 
The desired effect of radiation, namely irreparable DNA 
damage which ceased clonogens division, occurs at the time 
of irradiation. A lengthening of the interval between 
radio(chemo)therapy and surgery does not produce additional 
DNA damage. With delayed surgery, there is a risk of tumour 
regrowth and the development of a cancer phenotype that 
produces distant metastases. Indeed evaluation of a labelling 
index showed the accelerated proliferation of cancer cells in 
some tumours one month after 5 x 5 Gy. PET/CT 
examinations demonstrated increased metabolic activity in 
some tumours between 6 and 12 weeks after chemoradiation. 
Thus, the long interval potentially jeopardizes oncological 
outcomes in up-front resectable cancers. This effect, 
however, was not shown in the randomized studies or in the 
meta-analysis.  
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Purpose/Objective: In patients with rectal cancer 
(chemo)radiotherapy is usually followed by low anterior 
resection (LAR) or abdominoperineal resection (APR) with 
permanent colostomy. Type of surgery depends on tumor 
localization, patient's condition and surgeons' preference. 
Until now, there is still debate which procedure is superior in 
terms of quality of life (QoL). In this study we compare QoL 
during the first six months of treatment in patients 
undergoing LAR and APR. 
Materials and Methods: This study was performed in the 
context of the ProspectIve data CollectioN Iniative on 
Colorectal cancer (PICNIC) cohort. Within PICNIC patients fill 
out standardized QoL questionnaires at start of radiotherapy 
and every 3 months thereafter. In the present study, 
participants with rectal cancer who underwent curative 
surgery following radiotherapy between February 2013 and 
September 2014 were included. QoL was measured by means 
of EORTC QLQ-C30 and CR29, at baseline, 3 and 6 months. 
Responses were transformed to a longitudinal scale and 
reported as mean or median, depending on distribution. Mean 
differences in QoL scores were calculated and categorized as 
improved, stable and worsened. Differences in QoL were 
tested on significance with the Mann-Whitney U test and Chi-
square test. 
Results: One-hundred-fourteen patients were identified, 55 
(48%) underwent APR and 59 (52%) LAR. Baseline 
characteristics between were similar for both groups, except 
for tumor location (90.9% vs. 28.8% located in lower third of 
the rectum for APR and LAR resp.) and T-stage (66.7% vs. 
83.1% T3 tumors for APR and LAR resp.). At baseline, LAR 
patients reported a higher mean score for physical function 
(90 vs. 82, p= 0.008), role function (84 vs. 72, p= 0.008) and 
global health (75 vs. 66, p= 0.013) compared to APR patients. 
After 3 months, both groups reported similar differences in 
QoL function scales. At 6 months, global health recovered in 
APR patients to baseline levels or above (only 22.6% reported 
to worsen compared to baseline), while LAR patients showed 
slower recovery (with 43.5% worsened status). At 6 months, 
APR patients had worsened body image compared to LAR 
patients (mean difference -19 (-26.7 to -11.3) vs. -11 (15.8 to 
-6.8), p=0.01), but improved stool frequency (mean 
difference +18 (7.9 to 28.8) resp. -6 (-15.4 to 3.9) p=0.003). 
Regarding symptoms, LAR patients worsened on 
embarrassment for defecation pattern, while APR patients 
worsened on urine incontinence and impotence. 
Conclusions: The impact of surgery type on QoL during the 
first six months in rectal cancer patients pretreated with 
(chemo)radiation is similar for most domains. However, 
patients who underwent APR seem to recover more quickly in 
respective of their global QoL before treatment. Symptom 
patterns were quite different between patients undergoing 
LAR or APR. These results can be helpful in counseling 
patients in treatment choice, giving the large differences in 
patients' perspective, lifestyle, and expectations of 
treatment. 
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Purpose/Objective: To present an interim analysis of the 
trial of concurrent capecitabine and radiotherapy with or 
without oxaliplatin as adjuvant treatment for locally 
advanced rectal cancer.  
Materials and Methods: This was a multicentre, open-label, 
randomized, phase 3 study in patients with pathological stage 
II-III rectal cancer. Patients were randomized to either 
radiotherapy 45-50.4 Gy/25-28 fractions with concurrent 
capecitabine 1600 mg/m2 on days 1-14, 22-35 (Cap-RT group) 
or 45-50.4 Gy/25-28 fractions with capecitabine 1300 mg/m2 
on days 1-14, 22-35 and oxaliplatin 60 mg/m2 on weeks 1, 2, 
4, 5 (Capox-RT group). Randomization was done with 
computer-generated block-randomization codes stratified by 
centre and pathological stage (II vs. III) without masking. The 
primary endpoint was 3-year disease-free survival rate (DFS); 
secondary endpoints included overall survival rate (OS), 
locoregional failure free survival rate (LRFFS), distant 
metastasis free survival rate (DMFS), compliance, and safety. 
Safety and compliance analyses included patients as treated, 
efficacy endpoints were analysed according to the intention-
to-treat principle. This study is registered with 
ClinicalTrials.gov, number NCT00714077. 
Results: Providing 80% power to detect an increase of 3y-DFS 
from 65% to 75% (α=0.05, 2-tailed test), 570 patients were 
required. Between January 2008 and July 2014, 492 patients 
were recruited from 4 centers in China. Of these patients, 
478 were evaluable (254 in the Cap-RT group and 224 in the 
Capox-RT group), with a median follow-up of 34.6 months for 
patients alive. The 3-year DFS rate was 71.6% in the Capox-
RT group, as compared with 73.9% in the Cap-RT group (p= 
0.647). No statistically significant difference was observed in 
OS, LRFFS, and DMFS between the two groups (3-year OS: 
88.1% vs. 85.4%, p = 0.770; LRFFS: 91.9% vs. 96.1%, p = 0.079; 
DMFS: 76.1% vs. 74.3%, p = 0.934), but higher cumulative 
locoregional recurrence rate in the Cap-RT group (6.7% vs. 
